NCT05874310

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Frontera Therapeutics · Industry
• Sex: Male
• Age: 8 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

Conditions

• X-Linked Retinitis Pigmentosa

Interventions

Type	Name	Description
GENETIC	FT-002	Comparison of different dosages of FT-002

Timeline

• Start date: 2023-02-01
• Primary completion: 2023-10-31
• Completion: 2027-11-01
• First posted: 2023-05-24
• Last updated: 2023-05-24

Locations

2 sites across 1 country: China